3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
35
Carcinoid Tumor
8
Adenoma, Islet Cell
6
Neoplasms
5
Neoplasm Metastasis
3
Carcinoma, Neuroendocrine
3
Neuroectodermal Tumors, Primitive
2
Liver Neoplasms
2
Gastro-enteropancreatic neuroendocrine tumor
2
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Tuberous Sclerosis
1
Thymus Neoplasms
1
Pheochromocytoma
1
Paraganglioma
1
Pancreatic Neuroendocrine Tumors
1
Pancreatic Neoplasms
1
Neoplastic Cells, Circulating
1
Multiple Endocrine Neoplasia Type 1
1
Metatropic dwarfism
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Kidney Neoplasms
1
Glioblastoma
1
Gastroenteropancreatic Neuroendocrine Tumors
1
Disease Progression
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Large Cell
1
Interventions
Quality of Life
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Magnetic Resonance Spectroscopy
1
Immunotherapy
1
Fluorodeoxyglucose F18
1
FAPI-46
1
Everolimus
1
Drug Therapy
1
Biological Therapy
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thymus Neoplasms
×
Everolimus
×
NET
×
Clear all
NCT05918302
2026-05-12
LEVEL
Grupo Espanol de Tumores Neuroendocrinos
Phase 3
Recruiting
170 enrolled